[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,760
  • Shares Outstanding, K 107,122
  • Annual Sales, $ 33,030 K
  • Annual Income, $ -44,630 K
  • EBIT $ -38 M
  • EBITDA $ -33 M
  • 60-Month Beta 1.48
  • Price/Sales 3.89
  • Price/Cash Flow N/A
  • Price/Book 0.77

Options Overview Details

View History
  • Implied Volatility 290.19% (+34.10%)
  • Historical Volatility 84.04%
  • IV Percentile 53%
  • IV Rank 37.40%
  • IV High 745.15% on 02/03/26
  • IV Low 18.43% on 05/14/26
  • Expected Move (DTE 13) 0.0000 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 8
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 391
  • Open Int (30-Day) 350
  • Expected Range 1.2050 to 1.2050

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 2
  • High Estimate $-0.08
  • Low Estimate $-0.12
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7840 +50.51%
on 05/12/26
1.2950 -8.88%
on 06/01/26
+0.3373 (+40.03%)
since 05/05/26
3-Month
0.6593 +78.98%
on 03/30/26
1.2950 -8.88%
on 06/01/26
+0.3444 (+41.22%)
since 03/05/26
52-Week
0.6434 +83.40%
on 02/17/26
2.3800 -50.42%
on 06/10/25
-0.9700 (-45.12%)
since 06/05/25

Most Recent Stories

More News
MaxCyte Q1 Earnings Call Highlights

MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue,...

MXCT : 1.1750 (-4.47%)
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)
MaxCyte Announces Planned CFO Transition in 2026

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 1.1750 (-4.47%)

Business Summary

MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.

See More

Key Turning Points

3rd Resistance Point 1.3167
2nd Resistance Point 1.2833
1st Resistance Point 1.2567
Last Price 1.1750
1st Support Level 1.1967
2nd Support Level 1.1633
3rd Support Level 1.1367

See More

52-Week High 2.3800
Fibonacci 61.8% 1.7166
Fibonacci 50% 1.5117
Fibonacci 38.2% 1.3068
Last Price 1.1750
52-Week Low 0.6434

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.